Ampio completes enrollment in multiple indication diagnostic trials

The trials include patients reporting to the emergency department with chest pain and undergoing clinical evaluation including the performance of Positron Emission Tomography coupled to Computerized Axial Tomography (PET/CT).

The analysis of the results of the trials will decide the utility of the technology, based on which the company will begin preparing a 510(k) submission upon completion of data analysis.

Ampio CEO Michael Macaluso said that subsets of these patients will be analyzed for the use of ORP in hospital readmission prediction/prevention/reduction.

"The lack of a metric to determine preventable and non-preventable readmission is problematic and Ampio hopes that ORP measurements at or close to discharge may reduce readmission associated costs both to hospitals and insurers," Macaluso added.